Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CNCT19 in Refractory Autoimmune Diseases
NCT06316791Phase 1Recruiting
- Sponsor
- Juventas Cell Therapy Ltd.
- Start
- Dec 2021
- Primary completion
- Dec 2025
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of inaticabtagene autoleucel in systemic lupus erythematosus (SLE), lupus nephritis (LN), Antineutrophil cytoplasmic antibody-associated vasculitis (AAV) and 1 more, sponsored by Juventas Cell Therapy Ltd. Primary endpoint: Treatment-Emergent Adverse Events at 1 year. Started Dec 2021; status: recruiting.
02
Drugs
inaticabtagene autoleucel
03
Conditions
systemic lupus erythematosus (SLE)lupus nephritis (LN)Antineutrophil cytoplasmic antibody-associated vasculitis (AAV)dermatomyositis (DM)
Beyond the preview
Go deeper on NCT06316791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06316791.